505 related articles for article (PubMed ID: 34487060)
21. Will vaccine-derived protective immunity curtail COVID-19 variants in the US?
Mancuso M; Eikenberry SE; Gumel AB
Infect Dis Model; 2021; 6():1110-1134. PubMed ID: 34518808
[TBL] [Abstract][Full Text] [Related]
22. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021.
Brown CM; Vostok J; Johnson H; Burns M; Gharpure R; Sami S; Sabo RT; Hall N; Foreman A; Schubert PL; Gallagher GR; Fink T; Madoff LC; Gabriel SB; MacInnis B; Park DJ; Siddle KJ; Harik V; Arvidson D; Brock-Fisher T; Dunn M; Kearns A; Laney AS
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(31):1059-1062. PubMed ID: 34351882
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
[TBL] [Abstract][Full Text] [Related]
24. COVID outbreak after the 1st dose of COVID vaccine among the nursing home residents: What happened?
Ye P; Fry L; Liu H; Ledesma S; Champion JD
Geriatr Nurs; 2021; 42(5):1105-1108. PubMed ID: 34274688
[TBL] [Abstract][Full Text] [Related]
25. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.
Kissling E; Hooiveld M; Sandonis Martín V; Martínez-Baz I; William N; Vilcu AM; Mazagatos C; Domegan L; de Lusignan S; Meijer A; Machado A; Brytting M; Casado I; Murray JK; Belhillil S; Larrauri A; O'Donnell J; Tsang R; de Lange M; Rodrigues AP; Riess M; Castilla J; Hamilton M; Falchi A; Pozo F; Dunford L; Cogdale J; Jansen T; Guiomar R; Enkirch T; Burgui C; Sigerson D; Blanchon T; Martínez Ochoa EM; Connell J; Ellis J; van Gageldonk-Lafeber R; Kislaya I; Rose AM; Valenciano M; ;
Euro Surveill; 2021 Jul; 26(29):. PubMed ID: 34296676
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the anti-COVID-19 vaccination campaign in the Metropolitan Area of Milan (Lombardy Region, Northern Italy).
Russo AG; Tunesi S; Consolazio D; Decarli A; Bergamaschi W
Epidemiol Prev; 2021; 45(6):568-579. PubMed ID: 34791867
[TBL] [Abstract][Full Text] [Related]
27. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
Rastawicki W; Płaza K
Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021.
Britton A; Jacobs Slifka KM; Edens C; Nanduri SA; Bart SM; Shang N; Harizaj A; Armstrong J; Xu K; Ehrlich HY; Soda E; Derado G; Verani JR; Schrag SJ; Jernigan JA; Leung VH; Parikh S
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(11):396-401. PubMed ID: 33735160
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
[TBL] [Abstract][Full Text] [Related]
30. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.
Milman O; Yelin I; Aharony N; Katz R; Herzel E; Ben-Tov A; Kuint J; Gazit S; Chodick G; Patalon T; Kishony R
Nat Med; 2021 Aug; 27(8):1367-1369. PubMed ID: 34113015
[TBL] [Abstract][Full Text] [Related]
31. Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021.
Grgič Vitek M; Klavs I; Učakar V; Serdt M; Mrzel M; Vrh M; Fafangel M
Euro Surveill; 2022 Jan; 27(1):. PubMed ID: 34991780
[TBL] [Abstract][Full Text] [Related]
32. Covid-19 vaccine management (Comirnaty and mrna-1273 Moderna) in a teaching hospital in Italy: a short report on the vaccination campaign.
Papini F; Grassi N; Guglielmi G; Gattini V; Rago L; Bisordi C; Scateni M; Totaro M; Tulipani A; Porretta A; Tavoschi L; Guercini J; Luchini G; Briani S; Privitera GP; Baggiani A
Environ Health Prev Med; 2021 Sep; 26(1):99. PubMed ID: 34592930
[TBL] [Abstract][Full Text] [Related]
33. Prioritizing the First Doses of SARS-CoV-2 Vaccine to Save the Elderly: The Case Study of Italy.
Pontrelli G; Cimini G; Roversi M; Gabrielli A; Salina G; Bernardi S; Rocchi F; Simonetti A; Giaquinto C; Rossi P; Sylos Labini F
Front Public Health; 2021; 9():684760. PubMed ID: 34336771
[TBL] [Abstract][Full Text] [Related]
34. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
[No Abstract] [Full Text] [Related]
35. COVID-19 vaccination effectiveness rates by week and sources of bias.
Ostropolets A; Hripcsak G
medRxiv; 2021 Dec; ():. PubMed ID: 34981073
[TBL] [Abstract][Full Text] [Related]
36. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
37. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021.
de Gier B; Andeweg S; Joosten R; Ter Schegget R; Smorenburg N; van de Kassteele J; ; Hahné SJ; van den Hof S; de Melker HE; Knol MJ;
Euro Surveill; 2021 Aug; 26(31):. PubMed ID: 34355689
[TBL] [Abstract][Full Text] [Related]
38. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
Pritchard E; Matthews PC; Stoesser N; Eyre DW; Gethings O; Vihta KD; Jones J; House T; VanSteenHouse H; Bell I; Bell JI; Newton JN; Farrar J; Diamond I; Rourke E; Studley R; Crook D; Peto TEA; Walker AS; Pouwels KB
Nat Med; 2021 Aug; 27(8):1370-1378. PubMed ID: 34108716
[TBL] [Abstract][Full Text] [Related]
39. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
[TBL] [Abstract][Full Text] [Related]
40. Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak.
McEllistrem MC; Clancy CJ; Buehrle DJ; Lucas A; Pruskowski J; Handler SM; Decker BK
Am J Infect Control; 2021 Oct; 49(10):1237-1241. PubMed ID: 34363871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
